Sign in
Taking people in United StatesPhase 1

Tests NN3201, a c-Kit-targeted drug, in adults with advanced solid tumors

Tests NN3201 for safety in adults with advanced solid tumors that express c-Kit.

Key facts

Who runs it
Novelty Nobility, Inc.
Where
Ann Arbor, Cleveland, Fairfax, Houston, and Portland, United StatesSee the 5 sites
Trial code
Registry title
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Status
Recruiting
Phase
Phase 1
People taking part
67 people, planned
Started
3 Feb 2025
Expected to end
31 Dec 2027
Type of study
Interventional, 4 groups
Treatments tested
  • NN3201
Record updated
13 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or spread solid tumors that carry c-Kit and have not responded to usual treatment. Tumor types include GIST, small-cell lung cancer, adenoid cystic carcinoma, uveal melanoma, neuroendocrine tumors and kidney cancer.

Age
18 years or older
Sex
All sexes
Disease stage
Locally advanced, spread (metastatic) or unresectable GIST, SCLC, ACC, uveal melanoma, NET, ChRCC or ccRCC. The tumor must be confirmed under the microscope.
Earlier treatment
GIST: at least one line of imatinib. Other tumors: the cancer got worse or did not respond to standard therapy, the person cannot have or cannot tolerate it, or declines it. For extensive stage SCLC, the same applies in Part B. Waiting times after earlier cancer treatment are required, for example 21 days after cytotoxic chemotherapy.
Biomarker or test result
Tumors known to express c-Kit. Normal kidney, liver, bone marrow and heart function (ECHO/MUGA scan) is needed.

Main reasons for not taking part

  • Earlier treatment with a c-Kit drug (except GIST)
  • Brain metastases that are untreated, cause symptoms or need treatment
  • Major surgery within 30 days before the first dose
  • Active serious infection, or uncontrolled high blood pressure
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Subjects must meet the following criteria to be eligible for enrollment into the study:
  • Histologically or cytologically confirmed locally advanced, metastatic, and/or unresectable GIST, SCLC, ACC, uveal melanoma, NET ChRCC or ccRCC
  • Subjects must have received the following treatment:; Part A (Dose Escalation):; Treatment with imatinib for GIST (at least one line of therapy with imatinib); or; Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for c-Kit-associated solid tumors (ACC, uveal melanoma, NET ChRCC or ccRCC); Part B (Dose Expansion):; Treatment with imatinib for GIST (at least one line of therapy with imatinib) or; Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for Extensive stage SCLC or; Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for c-Kit-associated solid tumors (ACC, uveal melanoma, NET or ChRCC or ccRCC)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Life expectancy ≥ 3 months before starting NN3201 in the opinion of the Investigator
  • Age ≥ 18 years
  • Laboratory values demonstrating adequately functioning kidney, liver and bone marrow (hematology)
  • Adequate heart function as measured by ECHO/MUGA scan
  • Time between prior anticancer therapy including investigational agents and first dose of NN3201 as below:; Cytotoxic chemotherapy - At least 21 days; Non-cytotoxic chemotherapy (e.g., small molecule inhibitor) - At least 14 days; Nitrosoureas - At least 6 weeks; Monoclonal antibody(ies) - At least 28 days; Radiotherapy - At least 14 days from local site radiation therapy
  • Negative Serum/urine pregnancy test (for subjects of childbearing potential)
  • All subjects of childbearing potential must agree to use contraception throughout the study and for additional 120 days after the last dose of assigned treatment. Subjects must refrain from donating sperm during the same period or Subjects who do not have childbearing potential are confirmed post-menopausal or sterile
  • Voluntary agreement to provide written informed consent and have willingness and ability to comply with all aspects of the protocol

Who cannot take part

  • Has received prior therapy with a c-Kit agent (except GIST subjects)
  • Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms
  • A condition requiring systemic treatment with corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to administration of study drugs (inhaled corticosteroids are allowed)
  • Any prior treatment-related (i.e., chemotherapy, immunotherapy, radiotherapy) clinically significant toxicities that have not resolved to Grade ≤ 1 or prior treatment-related toxicities that are clinically unstable and clinically significant at Study Entry, Day -2 to Cycle 1 Day 1
  • Major surgery within 30 days before the first dose of study drug treatment in Cycle 1 on Day 1 (port placement for venous access is not considered major surgery)
  • Venous thrombosis or pulmonary embolism within the last 3 months prior to the screening
  • Ongoing or active infection requiring intravenous treatment with anti-infective therapy or systemic therapy and/or any identified active COVID-19 infection
  • Significant cardiovascular impairment
  • Known active and clinically significant bacterial, fungal, or viral infection
  • Uncontrolled hypertension defined as systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg, despite optimal medical management
  • Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the subject's participation in this study
  • Significant screening electrocardiogram (ECG) abnormalities
  • People who are pregnant or breastfeeding; Other inclusion and exclusion criteria must also be met to be eligible to participate in this study

Where in United States

  • University of Michigan HospitalsAnn Arbor, United StatesContact: Rashmi Chugh, MDTaking people
  • Case Comprehensive Cancer CenterCleveland, United StatesContact: Ankit Mangla, MDTaking people
  • NEXT VirginiaFairfax, United StatesContact: Clinical Trial LeadNo longer taking part
  • The University of Texas MD Anderson Cancer CenterHouston, United StatesContact: Dr. Jordi Rodon Ahnert, MD, PhDTaking people
  • Oregon Health Science UniversityPortland, United StatesContact: Michael Heinrich, MDTaking people

About the trial

What the trial wants to find out

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

The 4 groups in the trial

  • Part ATreatment being tested

    NN3201 administered intravenously every three weeks, the dosage to be determined by ascending dose cohort assignment. Part A will enroll patients that have GIST or Other c-Kit tumor disease types. This is an open-label multiple ascending dose study.

    Treatment: NN3201

  • Part B, Cohort 1 (GIST)Treatment being tested

    NN3201 administered intravenously every three weeks, expanding one or two doses in GIST disease type. This is an open-label multiple dose expansion study.

    Treatment: NN3201

  • Part B, Cohort 2 (SCLC)Treatment being tested

    NN3201 administered intravenously every three weeks, expanding one or two doses in SCLC disease type. This is an open-label multiple dose expansion study.

    Treatment: NN3201

  • Part B, Cohort 3 (other c-Kit tumors)Treatment being tested

    NN3201 administered intravenously every three weeks, expanding one or two doses in Other c-Kit tumor disease type. This is an open-label multiple dose expansion study.

    Treatment: NN3201

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Plain-language title
Tests NN3201, a c-Kit-targeted drug, in adults with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 November 2026